Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders
Maria Gabriella Brasca(Nerviano Medical Sciences), Daniele Donati(Nerviano Medical Sciences), Antonella Isacchi(Nerviano Medical Sciences), Nilla Avanzi(Nerviano Medical Sciences), Simona Bindi(Nerviano Medical Sciences), Marina Ciomei(Nerviano Medical Sciences), J. A. Bertrand(Nerviano Medical Sciences), Achille Panzeri(Nerviano Medical Sciences), M. Nesi(Nerviano Medical Sciences), Paola Gnocchi(Mario Negri Institute for Pharmacological Research), Eduard Felder, Daniele Casero(Nerviano Medical Sciences), Gabriele Fachin(Nerviano Medical Sciences), Ilaria Motto(Nerviano Medical Sciences), Sabrina Cribioli(Nerviano Medical Sciences), Nicoletta Colombo(University of Milano-Bicocca), Giulia Canevari(Nerviano Medical Sciences), Arturo Galvani(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia)
Cited by 20
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k